People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gemin X Pharmaceuticals Inc | — | Biotechnology | Series A | $13.2M | $141.6M | 2009 |
Peter R. Dolan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter R. Dolan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy J. Barberich | 1 | 7 |
| Robert G. McNeil | 1 | 5 |
| AARON DAVIDSON | 1 | 4 |
| Eric W. Roberts | 1 | 4 |
| ANDREW R. JORDAN | 1 | 2 |
| D. Michael Dixon | 1 | 2 |
| Robert Gorman | 1 | 2 |
| Gordon C. Shore | 1 | 1 |
| Robert J. Gorman | 1 | 1 |
| Scott J. Morenstein | 1 | 1 |
| Jean Michael Viallet | 1 | 1 |
| Jean Viallet | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.